Partners Ed Burbach and Frank Pasquesi have co-authored an article for Corporate Counsel, “2019: New Attorneys General and New Priorities,” about significant recent developments evidencing an increase in state AG activity throughout the country.
The article notes that there are 17 new state attorney generals this year, helping to make up what may be the most racially and gender diverse collection of state attorney generals in history. Moreover, the majority have backgrounds in legislative bodies or state agencies, rather than as prosecutors or in the judiciary, which suggests that policymaking through investigation and enforcement is becoming the norm. And, as those attorney generals become more active, the authors conclude, it is more important than ever to have on-the-ground local state attorney general experience.
(Subscription required.)
The article notes that there are 17 new state attorney generals this year, helping to make up what may be the most racially and gender diverse collection of state attorney generals in history. Moreover, the majority have backgrounds in legislative bodies or state agencies, rather than as prosecutors or in the judiciary, which suggests that policymaking through investigation and enforcement is becoming the norm. And, as those attorney generals become more active, the authors conclude, it is more important than ever to have on-the-ground local state attorney general experience.
(Subscription required.)
Author(s)
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”